Maxwell Y Lee (Maxwell Lee)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Breast Cancer Cells

Computed Tomography

Top Venues

Cancer research

The Laryngoscope

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Navdeep Malik, Young-Im Kim, Hualong Yan, Yu-Chou Tseng, Wendy D Dubois, Gamze Ayaz, Andy D Tran, Laura Vera Ramírez, Howard Hua Yang, Aleksandra M Michalowski, Michael J Kruhlak, Maxwell Y Lee, Kent W Hunter, Jing Huang
Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer. Cancer research (2023)
Maxwell Y Lee, Jonathan Lee, Sarah Stock, Mario Belfiglio, Brian Matia, Shlomo Koyfman, Nikhil P Joshi, Brian B Burkey, Eric D Lamarre, Brandon Prendes, Joseph Scharpf, Robert R Lorenz, Neil McIver Woody, David J Adelstein, Jessica L Geiger, Deborah J Chute, Jamie A Ku
Prognostic value of computed tomography scan detection of cartilage invasion in advanced laryngeal cancer treated with primary total laryngectomy. Head & neck 44 (10) (2022)
Maxwell Y Lee, Mario Belfiglio, Johnathan Zeng, Christopher W Fleming, Shlomo Koyfman, Nikhil P Joshi, Eric Lamarre, Brandon Prendes, Joseph Scharpf, Robert R Lorenz, Neil M Woody, David J Adelstein, Jessica L Geiger, Deborah J Chute, Jamie A Ku
Primary Total Laryngectomy versus Organ Preservation for Locally Advanced T3/T4a Laryngeal Cancer. The Laryngoscope (2022)
Maxwell Y Lee, Simon Metenou, Douglas E Brough, Helen Sabzevari, Ke Bai, Caroline Jochems, Jeffrey Schlom, Clint T Allen
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis. NPJ vaccines 6 (1) (2021)
Maxwell Y Lee, Yvette Robbins, Cem Sievers, Jay Friedman, Houssein Abdul Sater, Paul E Clavijo, Nancy Judd, Edward Tsong, Chris Silvin, Patrick Soon-Shiong, Michelle R Padget, Jeffrey Schlom, James Hodge, Christian Hinrichs, Clint T Allen
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. Journal for immunotherapy of cancer 9 (3) (2021)